Retinal disease modeling & safety assessment
Dry age-related macular degeneration (AMD)
Dry AMD model using iPSC-derived RPE cells exposed to chronic low-dose N-retinylidene-N-retinylethanolamine (A2E) and blue light to simulate lipofuscin photoactivation. The model recapitulates key features of dry AMD pathology, including RPE atrophy, oxidative stress, complement activation, and inflammatory signaling.
Comprehensive high content screening services for assessment of RPE health and function, including growth factor secretion (VEGF, PEDF), barrier integrity (TEER), phagocytosis, pigmentation and maturity markers, oxidative stress, complement activation, cell viability and apoptosis.
Automated 384‑well dry AMD screening platform enabling robust and reproducible screening of 6,000 compounds per run for preclinical drug discovery.
RPE-microglia co-culture model
iPSC-derived RPE cells and iPSC-derived microglia co-culture for modeling retinal inflammation and the impact of AMD-related stressors. RPE cells displayed increased sensitivity to A2E- and blue light–induced stress when co-cultured with microglia compared to monoculture conditions including microglial proliferation and elevated secretion of inflammatory cytokines.
Retinal organoids for discovery and retinal toxicity
Compound efficacy and toxicity testing using human iPSC‑derived retinal organoids, enabling assessment of therapeutic response, mechanism of action. Optimised retinal organoid-based screening systems for retinal toxicity with cell viability (ATP-based assays), morphological assessment, and short- and long-term treatment regimes.
iPSC lines from patients and unaffected donors
Extensive human iPSC line library including multiple retinopathies, Leber congenital amaurosis and Ushers syndrome type 1.
Human iPSC-derived retinal-related cell models for advanced in vitro modeling
Functional and well characterized retinal pigment epithelium (RPE) cells, retinal organoids (d60, d150, d180 and custom maturation) and microglia. Provision of scalable custom manufacturing from iPSC library, client lines or post-gene edit.
Retinal Pigment Epithelial (RPE) Cells
Ensure confidence in your workflow with high-quality Retinal Pigment Epithelial (RPE) cells differentiated from human induced pluripotent stem cells (iPSCs) and assay-ready in just 4 weeks. Derived from consenting donor PBMCs, our RPE cells have been specifically developed for use in powerful in vitro models and systems for drug discovery.
iPSC-derived retinal organoids contain the major retinal cell types organized in a laminar structure, as shown by the expression of Recoverin (photoreceptors), Rhodopsin (rods), Opsin LW/MW and SW (cones), PKC-α (bipolar cells), AP-2α (amacrine cells), SNCG (ganglion cells), CRALBP (Müller glial cells), and PROX1 (horizontal cells).
Specialist services
Services include reprogramming from patient cohort material and gene-editing. Custom differentiation of our iPSC lines, or client lines for retinal and ophthalmic research models, including retinal organoid generation. Preclinical drug discovery services, assay development, target validation, mode of action and safety.
